Is Syngenta Finally Settling Thousands of Paraquat Parkinson's Disease Lawsuits?

Master Settlement Agreement Signals Major Progress in Litigation Linking Weed Killer to Brain Disease

Syngenta has signed a Master Settlement Agreement with plaintiffs' attorneys representing thousands of people who developed Parkinson's disease after exposure to the company's paraquat weed killer, marking significant progress toward resolving over 6,700 pending U.S. lawsuits. The agreement follows a preliminary settlement reached in April 2025 and establishes a framework for compensating victims who claim the Chinese-owned agrochemical giant failed to warn users about the neurological risks of paraquat exposure. Within 60 to 90 days, plaintiffs will receive a payout schedule showing estimated settlement amounts, allowing them to decide whether to accept the offer or continue pursuing individual trials against the company.

Key Facts

• Over 6,700 U.S. lawsuits are pending against Syngenta alleging that paraquat causes Parkinson's disease.

• A Master Settlement Agreement has been signed following preliminary negotiations in April 2025

• Plaintiffs will receive payout schedules within 60-90 days to decide whether to participate.

• Scientific studies show paraquat damages brain cells in ways that can lead to Parkinson's disease.

• Internal documents reveal that Syngenta was aware of the links between paraquat and Parkinson's disease decades ago.

What Is the Current Status of the Paraquat Settlement Process?

The Master Settlement Agreement represents a crucial milestone in resolving thousands of paraquat lawsuits filed across the United States. According to recent court filings in Contra Costa County Superior Court, both parties have hired a settlement administrator and a lien negotiation administrator to facilitate the complex process of distributing compensation to affected individuals.

Khaldoun Baghdadi, one of the lead attorneys representing plaintiffs, told the court that a budgeting process is currently underway, with several thousand cases involved in the negotiations. The settlement structure will provide plaintiffs with individual choice, allowing them to opt in or out based on the compensation offered for their specific circumstances.

Why Are Farmers and Agricultural Workers Suing Syngenta?

The lawsuits against Syngenta center on allegations that the company engaged in a deliberate scheme to suppress knowledge about chronic health risks associated with paraquat exposure. Plaintiffs claim they developed Parkinson's disease, an incurable brain disorder, after using the herbicide in agricultural settings without adequate warnings about neurological dangers.

Paraquat has been widely used in American agriculture since the 1960s, applied in orchards, wheat fields, cotton fields, and pastures where livestock graze. Farmers use the chemical to control weeds before planting crops and to dry out crops for harvest, resulting in widespread occupational exposure among agricultural workers who trusted the product's safety based on Syngenta's representations.

What Evidence Links Paraquat to Parkinson's Disease?

Numerous scientific studies have established connections between paraquat exposure and Parkinson's disease development, contradicting Syngenta's public position that evidence remains "fragmentary" and "inconclusive." Research has demonstrated that paraquat damages brain cells in specific ways that can trigger the progressive neurological condition.

Internal Company Documents Reveal Decades of Knowledge

Internal Syngenta documents obtained by The New Lede and The Guardian reveal the company was aware of research connecting paraquat to Parkinson's disease decades ago. These files show not only awareness of the health risks but also efforts to secretly influence scientific information and public opinion regarding the paraquat-Parkinson's connection. The documents indicate a systematic approach to protecting the product's marketability despite known neurological risks.

How Will the Settlement Process Work for Plaintiffs?

The settlement implementation involves multiple stages designed to accommodate the large number of claimants while ensuring a fair distribution of compensation. Within the next two to three months, plaintiffs will receive detailed payout schedules showing the range of estimated settlement amounts based on factors likely to include exposure duration, disease severity, and economic damages.

Each plaintiff will maintain autonomy in deciding whether to accept the settlement offer or continue pursuing individual litigation. Baghdadi acknowledged to the court that not all plaintiffs are expected to accept the settlement, with some choosing to proceed to trial seeking potentially larger awards through jury verdicts.

What Happens to Cases That Don't Settle?

Despite the Master Settlement Agreement, individual trials may still proceed for plaintiffs who reject settlement offers. A trial is currently scheduled to begin in Philadelphia on October 6, though many legal observers express skepticism about whether it will actually commence given Syngenta's pattern of settling cases before reaching courtrooms.

The company recently settled a case that had been scheduled to start trial in late July or early August 2025, continuing a pattern of avoiding jury verdicts on the paraquat-Parkinson's allegations. This strategy suggests Syngenta may be concerned about the potential impact of adverse jury findings on remaining litigation and public perception.

How Does Paraquat Work and Where Is It Used?

Paraquat functions as a non-selective herbicide that destroys green plant tissue on contact, making it effective for weed control and crop desiccation. Introduced by a Syngenta predecessor company in the 1960s, the chemical has become one of the world's most widely used weed killers, despite being banned in over 30 countries, including the European Union and China, where Syngenta's parent company is based.

In the United States, paraquat remains a restricted-use pesticide requiring special licensing for application. Agricultural workers apply the chemical across diverse farming operations, from fruit orchards to grain fields, creating widespread exposure risks for rural communities and farm laborers who often lack adequate protective equipment or training about neurological hazards.

What Role Did Corporate Strategy Play in Concealing Risks?

The internal documents revealed through investigative journalism expose sophisticated corporate strategies to protect paraquat's market position despite known health risks. Syngenta's efforts included what internal communications referred to as a "SWAT team" approach to influence scientific discourse and regulatory decisions regarding paraquat safety.

These tactics allegedly involved funding favorable research, challenging independent studies linking paraquat to Parkinson's disease, and maintaining public messaging that emphasized uncertainty about health risks. The documents suggest a decades-long campaign to prioritize profits over public health by deliberately obscuring scientific evidence of neurological damage.

How Does This Settlement Compare to Other Agricultural Chemical Litigation?

The paraquat settlement negotiations occur within a broader context of agricultural chemical litigation that has reshaped the agrochemical industry. Bayer, which inherited over 100,000 Roundup cancer lawsuits when it acquired Monsanto in 2018, has paid billions in settlements and jury awards while continuing to face ongoing litigation.

Industry Push for Legal Protections

The mounting costs of chemical exposure litigation have prompted the agrochemical industry to lobby for federal and state legal protections that would limit future lawsuits. Led by Bayer, this legislative push aims to create barriers for plaintiffs seeking to hold manufacturers accountable for health damages resulting from pesticide exposure, potentially limiting future victims' ability to seek compensation.

What Are the Implications for Future Paraquat Use?

The settlement negotiations and ongoing litigation may influence regulatory decisions regarding the continued availability of paraquat in the United States. While the Environmental Protection Agency has maintained paraquat's registration with use restrictions, growing evidence of neurological risks and mounting legal costs could prompt reassessment of the chemical's risk-benefit profile.

Agricultural organizations face decisions about continuing paraquat use, given liability concerns and the availability of alternative weed control methods. Some farming operations have already transitioned away from paraquat to avoid potential health risks to workers and surrounding communities, accelerating the adoption of integrated pest management strategies.

What Should Current and Former Paraquat Users Know?

Individuals with occupational or environmental paraquat exposure should monitor for early Parkinson's disease symptoms, including tremors, stiffness, slow movement, and balance problems. Early detection and treatment can help manage symptoms and potentially slow disease progression, making medical vigilance crucial for populations at risk.

Former paraquat users diagnosed with Parkinson's disease may still have time to join litigation or participate in the settlement, depending on applicable statutes of limitations. Consulting with attorneys experienced in toxic exposure cases can help determine eligibility and assess whether accepting a settlement offer or pursuing individual litigation is better suited to serve their interests.

The Broader Impact on Agricultural Chemical Accountability

The paraquat litigation and settlement negotiations represent a significant moment in holding agrochemical companies accountable for product safety. The revelation of internal documents showing decades of knowledge about health risks, despite public denials, has implications beyond individual cases, potentially influencing regulatory oversight and corporate behavior across the industry.

As settlement discussions progress, the outcome will likely influence future litigation strategies for both plaintiffs and defendants in agricultural chemical exposure cases. The balance between providing timely compensation to victims and achieving full accountability for corporate misconduct remains a central tension as thousands of Parkinson's patients await resolution of their claims against Syngenta.